Abstract
Over the last decade, diagnostic options and introduction of novel treatments have expanded the armamentarium in the management of malignant glioma. Combined chemoradiotherapy has become the standard of care in glioblastoma up to the age of 70 years, while treatment in elderly patients or with lower grade glioma is less well defined. Molecular markers define different disease subtypes and allow for adapted treatment selection. This review focuses on simple questions arising in the daily management of patients.
Original language | English (US) |
---|---|
Pages (from-to) | x33-x40 |
Journal | Annals of Oncology |
Volume | 23 |
Issue number | SUPPL. 10 |
DOIs | |
State | Published - Sep 2012 |
Keywords
- Anaplastic astrocytoma
- Chemotherapy
- Glioblastoma
- IDH1
- MGMT
- Oligodendroglioma
ASJC Scopus subject areas
- Hematology
- Oncology